RACCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Research Alliance Corp III
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$10.23+0.07 (+0.69%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Research Alliance Corp III has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Research Alliance Corp III filed with the SEC
Oak Hill Bio and Research Alliance Corporation III Announce Business Combination Agreement to Create
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Confidential – Not to be Retained
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.2 to Form 8-K
Audited Financial Statement of Research Alliance Corporation III:
Other events · EX-99.1 to Form 8-K
ANNOUNCES PRICING OF $75 MILLION INITIAL PUBLIC OFFERING
Material agreement · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K